Comparison of three different definitions of low disease activity in patients with systemic lupus erythematosus and their prognostic utilities

被引:9
|
作者
Kang, Ji-Hyoun [1 ]
Shin, Min-Ho [2 ]
Choi, Sung-Eun [1 ]
Xu, Haimuzi [1 ]
Park, Dong-Jin [1 ]
Lee, Shin-Seok [1 ]
机构
[1] Chonnam Natl Univ, Med Sch & Hosp, Dept Internal Med, Div Rheumatol, 42 Jebong Ro, Gwangju 61469, South Korea
[2] Chonnam Natl Univ, Sch Med, Dept Prevent Med, Gwangju, South Korea
关键词
systemic lupus erythematosus; disease activity; damage; flare; quality of life; ACTIVITY STATE; INITIAL VALIDATION; DAMAGE; REMISSION; SLE; CLASSIFICATION; INDEX;
D O I
10.1093/rheumatology/keaa407
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Three definitions of low-level disease activity in patients with SLE have been proposed by different groups. These include minimal disease activity (MDA), low disease activity (LDA) and the lupus low disease activity state (LLDAS). We investigated the performance of these definitions in SLE patients. Methods We recruited 299 SLE patients who were followed up annually for 4 consecutive years. We compared the three definitions of low disease activity via longitudinal analysis; we used a generalized, linear-mixed effects model and generalized estimating equations. Results The LLDAS was significantly associated with a lower SLICC/ACR damage index (beta coefficient=-0.064, 95% CI: -0.129, -0.002, P=0.050), reduced flare (odds ratio = 0.090, 95% CI: 0.034, 0.239, P<0.001), an improved SF-36 physical component score (beta coefficient=0.782, 95% CI: 0.046, 1.519, P=0.037), and an improved SF-36 mental component score (beta coefficient=1.522, 95% CI: 0.496, 2.547, P=0.004). Neither the MDA nor the LDA were associated with these variables. Conclusion The LLDAS definition performs better than the MDA and LDA definitions, showing that LLDAS is associated with less organ damage and flare, and a better quality of life, during follow-up.
引用
收藏
页码:762 / 766
页数:5
相关论文
共 50 条
  • [21] Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort
    Petri, Michelle
    Magder, Laurence S.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (11) : 1790 - 1795
  • [22] Peripheral immunophenotypes associated with the flare in the systemic lupus erythematosus patients with low disease activity state
    Zheng, Jian
    Zhu, Li
    Ju, Bomiao
    Zhang, Jing
    Luo, Jing
    Wang, Yanhua
    Lv, XiaoHong
    Pu, Dan
    He, Lan
    Wang, Jing
    CLINICAL IMMUNOLOGY, 2022, 245
  • [23] Predictors of first hospitalization due to disease activity and infections in systemic lupus erythematosus patients
    Pons-Estel, Guillermo J.
    Quintana, Rosana
    Ugarte-Gil, Manuel F.
    Harvey, Guillermina B.
    Wojdyla, Daniel
    Serrano-Morales, Rosa
    Gomez Puerta, Jose A.
    Garcia, Mercedes A.
    Catoggio, Luis J.
    Saurit, Veronica
    Drenkard, Cristina
    Da Silva, Nilzio A.
    Cavalcanti, Fernando
    Borba, Eduardo
    Sato, Emilia
    Neira, Oscar
    Massardo, Loreto
    Vasquez, Gloria
    Gonzalez, Luis Alonso
    Guibert-Toledano, Marlene
    Silveira, Luis H.
    Garcia de la Torre, Ignacio
    Sauza del Pozo, Maria Josefina
    Chacon, Rosa
    Cardiel, Mario H.
    Orillion, Ashley
    Sbarigia, Urbano
    Alemao, Evo
    Zazzetti, Federico
    Alarcon, Graciela S.
    Pons-Estel, Bernardo A.
    LUPUS, 2024, 33 (13) : 1492 - 1501
  • [24] Assessment Of disease activity in Systemic Lupus Erythematosus: Lights and shadows
    Ceccarelli, Fulvia
    Perricone, Carlo
    Massaro, Laura
    Cipriano, Enrica
    Alessandri, Cristiano
    Spinelli, Francesca Romana
    Valesini, Guido
    Conti, Fabrizio
    AUTOIMMUNITY REVIEWS, 2015, 14 (07) : 601 - 608
  • [25] Antinucleosome antibodies in systemic lupus erythematosus patients: Relation to disease activity and lupus nephritis
    Elessawi, Dina F.
    Mahmoud, Geilan A.
    El-Sawy, Wael S.
    Shieba, Hala F.
    Goda, Shimaa M.
    EGYPTIAN RHEUMATOLOGIST, 2019, 41 (01) : 31 - 34
  • [26] Subscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage
    Choi, S. T.
    Kang, J. I.
    Park, I. -H.
    Lee, Y. W.
    Song, J. -S.
    Park, Y. -B.
    Lee, S. -K.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (05) : 665 - 672
  • [27] Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort
    Saccon, Francesca
    Zen, Margherita
    Gatto, Mariele
    Margiotta, Domenico Paolo Emanuele
    Afeltra, Antonella
    Ceccarelli, Fulvia
    Conti, Fabrizio
    Bortoluzzi, Alessandra
    Govoni, Marcello
    Frontini, Giulia
    Moroni, Gabriella
    Dall'Ara, Francesca
    Tincani, Angela
    Signorini, Viola
    Mosca, Marta
    Frigo, Anna Chiara
    Iaccarino, Luca
    Doria, Andrea
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (07) : 943 - 950
  • [28] Impact of cyclophosphamide on gonadotropins in menopausal systemic lupus erythematosus patients: Relation to disease activity and damage
    Elbakry, Samah A.
    Hamouda, Rasha M.
    Naguib, Marina W.
    Hussein, Safaa A.
    EGYPTIAN RHEUMATOLOGIST, 2020, 42 (03) : 207 - 211
  • [29] Pentraxin 3 is associated with disease activity but not atherosclerosis in patients with systemic lupus erythematosus
    Shimada, Yuki
    Asanuma, Yu Funakubo
    Yokota, Kazuhiro
    Yoshida, Yoshihiro
    Kajiyama, Hiroshi
    Sato, Kojiro
    Akiyama, Yuji
    Mimura, Toshihide
    MODERN RHEUMATOLOGY, 2014, 24 (01) : 78 - 85
  • [30] Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes
    Pawlak-Bus, K.
    Schmidt, W.
    Leszczynski, P.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (03) : 949 - 959